Invention Title:

IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA AND RSV

Publication number:

US20260273040

Publication date:

2026-09-17

Section:

Human necessities

Class:

A61K39/145

Inventors:

Kena Anne Swanson 🇺🇸 Pearl River, NY, United States

Lynn Marie Phelan 🇺🇸 Lake Hiawatha, NJ, United States

Fernando Martin Diaz 🇺🇸 Boston, MA, United States

Ramin Darvari 🇺🇸 Lexington, MA, United States

Advait Vijay Badkar 🇺🇸 Westford, MA, United States

Pirada Suphaphiphat Allen 🇺🇸 Congers, NY, United States

Bakul Subodh Bhatnagar 🇺🇸 North Reading, MA, United States

Fanyu Meng 🇺🇸 Whippany, NJ, United States

Nicholas Luksha 🇺🇸 North Andover, MA, United States

Jayesh Vijay Sonje 🇺🇸 Arlington, MA, United States

Serguei Tchessalov 🇺🇸 Billerica, MA, United States

Michael David Bruchsaler 🇺🇸 St. Charles, MO, United States

Wouter Joris Knapen 🇧🇪 Puurs, Belgium

Parag Kolhe 🇺🇸 Westford, MA, United States

Marjoh Anne Nauta 🇧🇪 Puurs, Belgium

Naomi Sasha Ramesar 🇺🇸 Wilmington, MA, United States

Vincent Jurgen L. Van Deyck 🇧🇪 Puurs, Belgium

Thijs Vanslembrouck 🇧🇪 Puurs, Belgium

Wei Chen 🇺🇸 Clliffside Park, NJ, United States

Bert George E. Van Meervenne 🇧🇪 Puurs, Belgium

Sarah Elizabeth Weiser 🇺🇸 Andover, MS, United States

Assignee:

PFIZER INC. 🇺🇸 New York, NY, United States

Applicant:

Pfizer Inc. 🇺🇸 New York, NY, United States

Smart overview of the Invention

The patent application discloses immunogenic compositions designed to protect against influenza and respiratory syncytial virus (RSV). These compositions include RNA molecules that encode influenza antigens, formulated in lipid nanoparticles (LNPs), and polypeptide antigens derived from RSV. The aim is to prevent illnesses caused by these viruses, addressing the limitations of traditional vaccines in terms of breadth and production speed, particularly during pandemics.

Technical Details

The compositions involve RNA vaccines encoding influenza antigens such as hemagglutinin (HA) and others like neuraminidase (NA) and nucleoprotein (NP). Additionally, these formulations include RSV polypeptides and/or polynucleotide molecules encoding RSV antigens. The RSV component focuses on the F protein, which is crucial for viral fusion and entry into host cells. The patent emphasizes the use of the pre-fusion form of the F protein, known for its stability and immunogenic potential.

Background

Influenza viruses pose a challenge due to their antigenic variability, making it difficult for traditional vaccines to provide broad protection. RSV is a major cause of respiratory illness in infants and the elderly, with no approved vaccines currently available. The F protein of RSV, particularly in its pre-fusion form, is a primary target for vaccine development due to its role in viral entry and its recognition by neutralizing antibodies.

Innovative Approach

The disclosed compositions aim to improve immunogenic responses against both RSV and influenza. They incorporate RNA sequences encoding RSV F proteins or their variants, potentially stabilized in a pre-fusion state. These compositions may also include commercially available influenza vaccines, enhancing their protective efficacy. The application suggests using vaccines like Flublok, Fluzone, Arexvy™, and ABRYSVO™ for comprehensive protection.

Potential Impact

By combining RNA-based influenza antigens with RSV polypeptides, the disclosed compositions offer a promising approach to vaccine development. This dual-target strategy could lead to more effective prevention of respiratory infections, addressing the urgent need for vaccines that can be rapidly adapted and produced during pandemics. The focus on pre-fusion RSV F proteins highlights a strategic approach to enhance vaccine efficacy and durability.